BioSpace News Archive

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today reported its financial results for the fourth quarter and year ended December 31, 2021.

Azenta, Inc. announced that Company management will participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, which includes a presentation beginning at 9:30am ET.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced that the company presented on advances with its novel immunostimulatory antibody-drug conjugate (iADC) modality at the 12th Annual World ADC conference taking place virtually and in London, from March 29 through April 1, 2022.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced it has formed a new leadership structure.

Stealth BioTherapeutics Corp (Nasdaq: MITO), announced today the presentation of new SBT-272 preclinical data at the Mitochondrial Biochemistry in Health and Disease Symposium in Breckenridge, CO and dosing of the first subject in its Phase 1 clinical trial of SBT-272.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the fourth quarter and year ended December 31, 2021.

According to a new preliminary study, children and teens with Tourette syndrome who are treated with an experimental drug called ecopipam may have improved scores on tests of tic severity three months later.

CStone Pharmaceuticals (“CStone”, HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the first patient has been enrolled in the U.S. in the Phase 1 clinical trial for CS5001.

Everest Medicines (HKEX 1952.HK), announced today that it has submitted a New Drug Application (NDA) to the Department of Health, the Hong Kong Special Administrative Region, China for sacituzumab govitecan.